To register or to learn more please visit:

Transcription

1 A Multitumor Regional Symposium Focused on the Application of Emerging Research Information to the Care of Patients with Common Cancers When Saturday, October 29, :00 AM to 4:00 PM Where JW Marriott Orlando Grande Lakes 4040 Central Florida Parkway Orlando, FL Palazzo A-D (Lobby Level) Breakfast and lunch provided Moderator Neil Love, MD Research To Practice Miami, Florida This activity is being hosted in association with Faculty and Topics Non-Small Cell Lung Cancer Melissa Johnson, MD Sarah Cannon Research Institute Nashville, Tennessee Geoffrey R Oxnard, MD Dana-Farber Cancer Institute Boston, Massachusetts Naiyer A Rizvi, MD Memorial Sloan Kettering New York, New York Breast Cancer William J Gradishar, MD Robert H Lurie Comprehensive Northwestern University Feinberg School of Medicine Chicago, Illinois George W Sledge Jr, MD Stanford University School of Medicine Stanford, California Melanoma Jason J Luke, MD The University of Chicago Chicago, Illinois Jeffrey Weber, MD, PhD NYU Langone Medical Center New York, New York Genitourinary Cancers Elizabeth R Plimack, MD, MS Fox Chase Philadelphia, Pennsylvania David I Quinn, MBBS, PhD USC Norris Comprehensive Los Angeles, California Hodgkin and Non-Hodgkin Lymphomas Ian W Flinn, MD, PhD Sarah Cannon Research Institute Nashville, Tennessee Loretta J Nastoupil, MD The University of Texas MD Anderson Houston, Texas Michael E Williams, MD, ScM University of Virginia School of Medicine Charlottesville, Virginia Multiple Myeloma Kenneth C Anderson, MD Dana-Farber Cancer Institute Boston, Massachusetts Robert Z Orlowski, MD, PhD The University of Texas MD Anderson Houston, Texas Colorectal, Gastric & Pancreatic Cancer Tanios Bekaii-Saab, MD Mayo Clinic Scottsdale, Arizona Philip A Philip, MD, PhD Karmanos Cancer Institute Wayne State University Detroit, Michigan To register or to learn more please visit: w w w.researchtopr ac tice.com /Meetings/ Y IR 2016/FL This event is free of charge. Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Research To Practice designates this live activity for a maximum of 6.75 AMA PRA Category 1 Credits TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity is supported by educational grants from AbbVie Inc, Acerta Pharma, Agendia Inc, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCarePharmaceuticals, biotheranostics Inc, Boston Biomedical Pharma Inc, Bristol-Myers Squibb Company, Celgene Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Janssen Biotech Inc, Lilly, Medivation Inc, Merrimack Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Sanofi, Seattle Genetics, Taiho Oncology Inc and Takeda Oncology.

2 CME Information Target Audience These live activities have been designed to meet the educational needs of medical oncologists, hematologists, hematologyoncology fellows, nurse practitioners, clinical nurse specialists and other allied cancer professionals. Learning Objectives and Goals At the conclusion of each activity, participants should be able to: Effectively apply the results of practicechanging clinical research to the care of patients with breast, lung, gastrointestinal, genitourinary, dermatologic and select hematologic cancers. Appraise the clinical relevance of recent pivotal cancer research results published in peer-reviewed journals and/or presented at major oncology conferences. Recall ongoing trials in breast, lung, gastrointestinal, genitourinary, dermatologic and select hematologic cancers, and refer appropriate patients for study participation. Use an understanding of tumor biomarkers and single and multigene signatures to individualize the care of patients with cancer. Educate patients with diverse hematologic cancers and solid tumors about the benefits and risks of new therapeutic agents and strategies. Refine or validate existing cancerspecific treatment algorithms based on exposure to new data sets and the perspectives of tumor-specific clinical investigators. Recognize immune-related adverse events and other common side effects associated with approved and developmental immunotherapeutics in order to offer supportive management strategies. Evaluate the mechanisms of action, tolerability and efficacy of promising investigational agents, and consider their potential implications for clinical practice. CME Credit Form A credit form will be given to each participant at the conclusion of each activity. Accreditation Statement Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. Credit Designation Statement Research To Practice designates each of these live activities for a maximum of 6.75 AMA PRA Category 1 Credits. Physicians should claim only the credit commensurate with the extent of their participation in the activity. Disclosure Policy Research To Practice (RTP) is committed to providing its participants with highquality, unbiased and state-of-the-art education. We assess conflicts of interest with faculty, planners and managers of CME activities. Conflicts of interest are identified and resolved through a conflict of interest resolution process. In addition, all activity content is reviewed by both a member of the RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations. Financial disclosures will be provided in meeting course materials. Educational Suppor t These activities are supported by educational grants from AbbVie Inc, Acerta Pharma, Amgen Inc, Astellas Pharma Global Development Inc, AstraZeneca Pharmaceuticals LP, Bayer HealthCare Pharmaceuticals, biotheranostics Inc, Boston Biomedical Pharma Inc, Bristol- Myers Squibb Company, Celgene Corporation, Eisai Inc, Exelixis Inc, Foundation Medicine, Genentech BioOncology, Genomic Health Inc, Janssen Biotech Inc, Lilly, Medivation Inc, Merrimack Pharmaceuticals Inc, Novartis Pharmaceuticals Corporation, Pharmacyclics LLC, an AbbVie Company, Prometheus Laboratories Inc, Sanofi, Seattle Genetics, Taiho Oncology Inc and Takeda Oncology.

3 Agenda All events will take place from 8:00 AM to 4:00 PM (breakfast and lunch buffets to be provided). Each module will include a moderated slide presentation reviewing key publications, presentations and ongoing trials in addition to a clinical decision-making track facilitated through the use of networked tablet technology. MODULE 1: Non-Small Cell Lung Cancer (NSCLC) EGFR mutation variants and selection of first-line therapy Role of rebiopsy and serum and urine genomic assays for patients with progressive EGFR mutation-positive NSCLC; clinical implications of T790M resistance mutations Next-generation EGFR tyrosine kinase inhibitors: Osimertinib available safety and efficacy data, FDA approval and indications for use in clinical practice Preliminary activity and ongoing evaluation of next-generation EGFR tyrosine kinase inhibitors under development Testing for ALK rearrangements; FISH versus next-generation sequencing; optimal first-line treatment and CNS efficacy of the 3 approved agents; FDA approval of alectinib Identification and clinical management of other potentially targetable mutations in NSCLC (eg, RET, BRAF, HER2) Available data with immune checkpoint inhibitors for patients with nonsquamous and squamous cell : Efficacy, toxicity and predictors of response, including PD-L1 expression; treatment for patients with preexisting autoimmune Emerging research information with anti- PD-L1 antibodies in NSCLC Ongoing clinical trials of anti-pd-1/pd-l1 antibodies alone or in combination with other systemic approaches Optimal first-line treatment of metastatic squamous cell cancer; role of necitumumab and management of associated toxicities (eg, dermatologic, hypomagnesemia) Second-line treatment of NSCLC and role of ramucirumab MODULE 2: Breast Cancer Available and emerging data guiding the use of genomic assays to optimize decision-making regarding adjuvant chemotherapy and extended endocrine therapy Clinical factors affecting the selection and sequence of systemic therapy for patients with ER-positive metastatic breast cancer (mbc) Integration of palbociclib into clinical algorithms for patients with ER-positive mbc Emerging research with other CDK4/6 inhibitors (eg, abemaciclib, ribociclib) Optimal therapy selection for patients with triple-negative breast cancer (TNBC) in the preoperative, adjuvant and metastatic settings Current clinical research in TNBC, including PARP inhibitors in patients with BRCA germline mutations and anti-pd-1 and anti-pd-l1 antibodies, androgen receptor assays and novel antiandrogens for metastatic Importance of age, tumor size, nodal status and primary surgical approach in the use of neoadjuvant anti-her2 therapy Ongoing and planned clinical trials incorporating novel HER2-directed therapies in the neoadjuvant and adjuvant settings Trials evaluating the use of dual anti- HER2 treatment: PHEREXA study of capecitabine/pertuzumab/trastuzumab; clinical decision-making in HER2-positive mbc MODULE 3: Colorectal, Gastric and Pancreatic Cancer Recommendation for assessment of tumor biomarkers in patients with metastatic colorectal cancer (mcrc), including RAS, BRAF, HER2, PD-1 and microsatellite instability (MSI)

4 Current available data on the use of checkpoint antibodies in MSI-high colorectal cancer and current clinical indications for the use of these agents Anti-HER2 agents in the management of HER2-amplified mcrc Clinical approach to up-front therapy for patients with BRAF tumor mutations; role of FOLFOXIRI; use of BRAF inhibitors in mcrc Second-line treatment of RAS wild-type mcrc: Role of bevacizumab continuation, ramucirumab and aflibercept Toxicity considerations with the use of regorafenib and TAS-102 as later-line treatment; optimal sequencing Optimal management of HER2-positive gastric cancer that progresses on firstline trastuzumab/chemotherapy Available efficacy and safety data with checkpoint antibodies in patients with metastatic gastric or gastroesophageal junction cancer; active and proposed studies; emerging data in hepatocellular cancer Ongoing evaluation and current nonresearch role of FOLFIRINOX or nanoparticle albumin-bound (nab) paclitaxel/ gemcitabine in the neoadjuvant and adjuvant settings Optimal integration of MM-398 into clinical practice: Side effects and toxicities Ongoing investigation of other novel agents and strategies in gastrointestinal cancer MODULE 4: Genitourinary Cancers Available research data with enzalutamide and abiraterone for nonmetastatic castration-resistant prostate cancer (CRPC); potential roles in clinical practice Clinical factors affecting the sequence and selection of secondary hormonal therapy, immunotherapy and cytotoxic therapy for patients with metastatic CRPC (eg, prior therapies, age, performance status, symptomatology, sites of metastases) Emerging research information on AR-V7 as a biomarker to predict resistance to secondary hormonal therapy Differential mechanisms of action and available research data with other novel antiandrogens under development (eg, ARN-509, galeterone) Patient-specific considerations in the selection of first-line therapy for metastatic renal cell carcinoma (mrcc) (eg, age, performance status, comorbidities) Selection of a taxane for metastatic prostate cancer: Docetaxel versus cabazitaxel Currently available data supporting the use of checkpoint inhibitors in mrcc and predictors of response Current role of radium-223 chloride in clinical practice and rational combination strategies Emerging research information with cabozantinib and lenvatinib in mrcc; potential roles in clinical practice Current and future role of checkpoint inhibitors in metastatic bladder cancer and specific indications for the FDAapproved anti-pd-l1 agent atezolizumab MODULE 5: Hodgkin and Non-Hodgkin Lymphomas Selection of up-front treatment for chronic lymphocytic leukemia in younger and older patients with normal- and highrisk cytogenetics: FCR versus bendamustine/rituximab; roles of ibrutinib, idelalisib and obinutuzumab Efficacy of venetoclax; prevention of tumor lysis syndrome Optimal sequencing of ibrutinib, bortezomib and lenalidomide for relapsed/ refractory (R/R) mantle-cell lymphoma Role of obinutuzumab/bendamustine and idelalisib in R/R follicular lymphoma Similarities and differences between approved and developmental PI3 kinase inhibitors (eg, copanlisib, duvelisib) and potential clinical implications Application of AETHERA trial results to clinical practice; patient selection for brentuximab vedotin (BV) consolidation after autologous stem cell transplant Incidence, recognition and management of BV side effects and toxicities Anti-PD-1/PD-L1 antibodies in Hodgkin lymphoma: Available safety and efficacy data and ongoing evaluation

5 Agenda (continued) Current role of CD30 analysis for patients with T-cell lymphoma; potential role of BV in CD30-positive Patient- and/or -specific factors guiding the sequence and selection of belinostat, pralatrexate and romidepsin in T-cell lymphoma Available data and ongoing investigation of R 2 -CHOP in newly diagnosed diffuse large B-cell lymphoma (DLBCL); current role of lenalidomide in R/R DLBCL CD30 testing and indications for BV in B-cell lymphomas Novel strategies under active investigation in hematologic cancer: chimeric antigen receptor T-cell therapy, denintuzumab mafodotin and new Bruton tyrosine kinase inhibitors, such as acalabrutinib MODULE 6: Multiple Myeloma Current role of autologous stem cell transplantation in the era of novel agents Optimal selection of induction therapy in the transplant and nontransplant settings: 2 versus 3 drugs; choice of proteasome inhibitor Correlation between minimal residual status and clinical outcomes; implications for nonresearch care and ongoing trial design Clinical trial evidence to guide the selection of post-transplant and nontransplant maintenance and consolidation therapy for patients with normal- and high-risk Available clinical trial data with the use of daratumumab alone or combined with a proteasome inhibitor in the R/R setting Current role of elotuzumab with lenalidomide in R/R ; therapy for patients with progression on maintenance lenalidomide Ixazomib: Efficacy and tolerability; current and future use Current role of panobinostat with a proteasome inhibitor in R/R Emerging clinical trial evidence supporting the use of checkpoint inhibitors with immunomodulatory drugs; use of chimeric antigen receptor T-cell therapy New approaches to managing smoldering myeloma Current management of Waldenström macroglobulinemia MODULE 7: Melanoma Current role of adjuvant ipilimumab in clinical practice Mechanism of action and administration of talimogene laherparepvec; rational integration into clinical practice Available data with anti-pd-1 monotherapy and combinations with anti- CTLA-4 agents for previously untreated metastatic ; role of PD-L1 assays in clinical decision-making Incidence and management of autoimmune toxicities associated with immune checkpoint inhibitors Current role, if any, of high-dose interleukin-2 in the management of metastatic melanoma Indications for the use of immunotherapy as first-line treatment for BRAF-positive Clinical use of BRAF and MEK inhibitor combinations (vemurafenib/dabrafenib, trametinib/cobimetinib) Incidence, prevention and management of side effects and toxicities associated with available BRAF and MEK inhibitor combinations Management approach for patients with documented BRAF mutation-positive brain metastases Incidence of NRAS mutations in patients with metastatic melanoma; optimal therapeutic intervention Please consult for a detailed schedule including module order and times for each program.